109 related articles for article (PubMed ID: 36400317)
1. Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity.
Chen CH; Weng TH; Chuang CH; Huang KY; Huang SC; Chen PR; Huang HH; Huang LY; Shen PC; Chuang PY; Huang HY; Wu YS; Chang HC; Weng SL; Liao KW
Nanomedicine; 2023 Jan; 47():102628. PubMed ID: 36400317
[TBL] [Abstract][Full Text] [Related]
2. A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.
Chen CH; Weng TH; Huang HH; Huang LY; Huang KY; Chen PR; Yeh KY; Huang CT; Chien YT; Chuang PY; Lin YL; Tsai NM; Liu SJ; Su YC; Weng SL; Liao KW
J Exp Clin Cancer Res; 2023 Jan; 42(1):29. PubMed ID: 36691089
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.
Lin YL; Chen CH; Wu HY; Tsai NM; Jian TY; Chang YC; Lin CH; Wu CH; Hsu FT; Leung TK; Liao KW
J Nanobiotechnology; 2016 Feb; 14():11. PubMed ID: 26892504
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation of
Huang XF; Chang KF; Lin YL; Liao KW; Hsiao CY; Sheu GT; Tsai NM
Int J Med Sci; 2021; 18(13):2930-2942. PubMed ID: 34220320
[TBL] [Abstract][Full Text] [Related]
5. Encapsulated
Lin YL; Huang XF; Chang KF; Liao KW; Tsai NM
Int J Nanomedicine; 2020; 15():749-760. PubMed ID: 32099363
[TBL] [Abstract][Full Text] [Related]
6. Antitumor Effect of
Gao HW; Chang KF; Huang XF; Lin YL; Weng JC; Liao KW; Tsai NM
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563276
[TBL] [Abstract][Full Text] [Related]
7. Low Molecular Weight Heparin-Coated and Dendrimer-Based Core-Shell Nanoplatform with Enhanced Immune Activation and Multiple Anti-Metastatic Effects for Melanoma Treatment.
Xia C; Yin S; Xu S; Ran G; Deng M; Mei L; Tang X; Rao J; Li M; Zhang Z; He Q
Theranostics; 2019; 9(2):337-354. PubMed ID: 30809278
[TBL] [Abstract][Full Text] [Related]
8. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies.
Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW
J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
[TBL] [Abstract][Full Text] [Related]
11. Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules.
Ho SY; Chen PR; Chen CH; Tsai NM; Lin YH; Lin CS; Chuang CH; Huang XF; Chan YL; Liu YK; Chung CH; Weng SL; Liao KW
J Nanobiotechnology; 2020 Apr; 18(1):58. PubMed ID: 32272948
[TBL] [Abstract][Full Text] [Related]
12. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
13. CpG-ODN-based immunotherapy is effective in controlling the growth of metastasized tumor cells.
Kim HA; Ko HM; Ju HW; Kim KJ; Roh SG; Lee HK; Im SY
Cancer Lett; 2009 Feb; 274(1):160-4. PubMed ID: 18952369
[TBL] [Abstract][Full Text] [Related]
14. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
[TBL] [Abstract][Full Text] [Related]
15. Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.
Lin YL; Chang KF; Huang XF; Hung CL; Chen SC; Chao WR; Liao KW; Tsai NM
Int J Nanomedicine; 2015; 10():6009-20. PubMed ID: 26451107
[TBL] [Abstract][Full Text] [Related]
16. Framework Nucleic Acid Immune Adjuvant for Transdermal Delivery Based Chemo-immunotherapy for Malignant Melanoma Treatment.
Shen F; Sun L; Wang L; Peng R; Fan C; Liu Z
Nano Lett; 2022 Jun; 22(11):4509-4518. PubMed ID: 35594186
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral CpG oligodeoxynucleotide treatment inhibits tumor growth and metastasis of B16F10 melanoma cells.
Kunikata N; Sano K; Honda M; Ishii K; Matsunaga J; Okuyama R; Takahashi K; Watanabe H; Tamura G; Tagami H; Terui T
J Invest Dermatol; 2004 Aug; 123(2):395-402. PubMed ID: 15245441
[TBL] [Abstract][Full Text] [Related]
18. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells.
Lin YL; Liu YK; Tsai NM; Hsieh JH; Chen CH; Lin CM; Liao KW
Nanomedicine; 2012 Apr; 8(3):318-27. PubMed ID: 21704596
[TBL] [Abstract][Full Text] [Related]
19. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
[TBL] [Abstract][Full Text] [Related]
20. Preparation of an injectable doxorubicin surface modified cellulose nanofiber gel and evaluation of its anti-tumor and anti-metastasis activity in melanoma.
Alizadeh N; Akbari V; Nurani M; Taheri A
Biotechnol Prog; 2018 Mar; 34(2):537-545. PubMed ID: 29314760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
